A Phase 3, Global, Multicenter, Open-Label Study to Investigate the Efficacy of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve, HCV GT1b-Infected Patients, With Non-severe Fibrosis
Phase of Trial: Phase III
Latest Information Update: 30 Jan 2018
At a glance
- Drugs Elbasvir/grazoprevir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms STREAGER
- 25 Jan 2018 Planned End Date changed from 1 Oct 2017 to 1 Feb 2018.
- 25 Jan 2018 Planned primary completion date changed from 1 Oct 2017 to 1 Feb 2018.
- 25 Jan 2018 Status changed from not yet recruiting to recruiting.